IDH1 and oligodendroglioma: Today, the mainstream holds the opinion1 that for WHO grade 2–3 oligodendrogliomas with IDH mutations and 1p/19q co-deletion should focus on neurological protection during the operation because they are sensitive to chemoradiotherapy.